Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
As models get better and platforms expand horizontally, what do you still own that remains durable and defensible?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results